Oriola-KD's revised guidelines on net sales and operating profit for 2010

Oriola-KD Corporation Stock Exchange Release 21 December 2010 at 9.00 a.m.


Guidelines issued on 28 October 2010

Oriola-KD's net sales from its continuing operations for 2010 are expected to be
higher than in 2009 and operating profit is forecasted to be clearly lower than
in 2009. The operating result of Pharmaceutical Trade Russia, including the
recognised one-off costs in the third quarter, is expected to be negative.

Revised guidelines issued on 21 December 2010

Oriola-KD's net sales from continuing operations, excluding Healthcare and
Dental Trade businesses, is expected to be some EUR 1.9 billion and operating
profit, excluding one-off costs, is expected to be some EUR 20 million in 2010.
One-off costs are expected to be in total some EUR 13 million in 2010, including
a provision related to the restructuring of Oriola-KD's Swedish Pharmaceutical
Wholesale operations in the fourth quarter of 2010.

Oriola-KD's operating profit for 2010 for continued and discontinued operations,
gain on sales of assets and one-off costs is expected to be some EUR 106
million.

The operating loss of Pharmaceutical Wholesale Russia decreases significantly
Oriola-KD's operating profit in 2010. Operations in Sweden and Finland have
developed according to plan.

Oriola-KD Corporation

Eero Hautaniemi
President and CEO


Kimmo Virtanen
Executive Vice President and CFO


Further information:

Kimmo Virtanen
Executive Vice President and CFO
tel. +358 (0)10 429 2069
e-mail: kimmo.virtanen@oriola-kd.com

Pellervo Hämäläinen
Vice President, Communications and Investor Relations
tel. +358 (0)10 429 2497
e-mail: pellervo.hamalainen@oriola-kd.com

Distribution
NASDAQ OMX Helsinki Ltd
Principal media

Published by:
Oriola-KD Corporation
Corporate Communications
Orionintie 5
FI-02200 Espoo, Finland
www.oriola-kd.com


[HUG#1474366]